Clinical trials: Nevus
Melanoma
Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma
The purpose of this study is to evaluate if precisely-targeted radiation therapy, known as stereotactic ablative radiotherapy (SART), given during treatment with the drug ipilimumab (Yervoy) will improve survival for patients…
- Trial name
- SART (NCT01565837)
- Testing
- Ipilimumab, Stereotactic Ablative Radiosurgery (SART)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wolfram Samlowski
Intraocular Melanoma, Melanoma (Skin)
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating patients who have…
- Trial name
- NCT00003802
- Testing
- pyrazoloacridine
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MELANOMA, SKIN NEOPLASMS
Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma
Cutaneous melanoma frequently develops cutaneous and subcutaneous metastases, which may cause significant morbidity and negatively affect quality of life.
- Trial name
- NCT07404605
- Testing
- Electrochemotherapy
- Where
- Slovenia
- Volunteers
- 150 people
- Sponsor
- Institute of Oncology Ljubljana
Healthy Skin, Nevus
The Application of Non-invasive and Cellular Level Resolution Fullfield Optical Coherence Tomography: Establishment and Analysis of Subcutaneous Cellular Level Image Database of Anatomical Locations in Healthy Volunteers and Evaluation of Usability
ApolloVue® S100 Image System is a medical device class II. The objective of this protocol is to image skin of healthy volunteers and to evaluate the performance of full-field optical coherence tomography (FF-OCT) device - the…
- Trial name
- NCT04406454
- Testing
- ApolloVue® S100 Image System
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Metastatic Malignant Melanoma
Inducing Systemic Immunity and Regressions in Metastatic Melanoma
In patients with multiple metastatic nodules of melanoma, the investigators evaluated whether autologous cytokines injected into cutaneous metastases would induce a systemic immune response as evidenced by the accumulation of…
- Trial name
- NCT02350972
- Testing
- Autologous cytokines
- Volunteers
- 88 people
- Sponsor
- NYU Langone Health
Melanoma
Safety of Intranodal ECI-006 in Melanoma Patients
The purpose of this study is to assess the safety and tolerability of cancer immunotherapy ECI-006 and to determine its ability to induce a measurable immune response against the tumor associated antigens.
- Trial name
- NCT03394937
- Testing
- ECI-006
- Where
- 9 sites in Belgium, Spain
- Volunteers
- 21 people
- Sponsor
- eTheRNA immunotherapies
Melanoma (Skin)
Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00492505
- Testing
- cisplatin, sorafenib tosylate, tamoxifen citrate
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- San Diego Pacific Oncology & Hematology Associates
Malignant Melanoma
Reducing Symptom Burden Through Physical Exercise in Melanoma Patients
The aim of the clinical trial is to determine whether regular exercise can reduce fatigue in adult patients with stage IIb-IV melanoma undergoing immunotherapy or targeted therapy.
- Trial name
- RESPECT (NCT06985056)
- Testing
- Supervised 12-week Resistance and Endurance Exercise Program
- Where
- Germany
- Volunteers
- 86 people
- Sponsor
- Universität Duisburg-Essen
Ocular Melanoma, Uveal Melanoma
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
This study will evaluate patients who have ocular melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatments and will be followed until death.
- Trial name
- FOCUS (NCT02678572)
- Testing
- Melphalan/HDS
- Where
- 22 sites in United States, Austria and 7 more
- Volunteers
- 102 people
- Sponsor
- Delcath Systems Inc.
Malignant Melanoma
Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma
This is a randomized non-blinded pilot study for patients with melanoma staging cT2N0M0 who are candidates for surgical resection.
- Trial name
- NCT03034395
- Testing
- Wide Local Excision
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Kansas Medical Center
Choroidal Melanoma
Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma
A prospective, experimental, case series of 20 patients, with choroidal melanoma, in which pars plana vitrectomy and Silicone oil as vitreous substitute will be used as intraocular shielding for attenuating the deleterious…
- Trial name
- NCT01460810
- Testing
- 1000CsK Silicon Oil Tamponade
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT02771626
- Testing
- CB-839, Nivolumab
- Where
- 17 sites in United States
- Volunteers
- 118 people
- Sponsor
- Calithera Biosciences, Inc
Skin Cancer, Skin Cancer Melanoma
Strategies to Promote Skin Health
The purpose of the intended proposed research is to investigate and determine best strategies for preventing skin cancer for emerging adults.
- Conditions
- Skin Cancer, Skin Cancer Melanoma, Squamous Cell Carcinoma, Basal Cell Carcinoma
- Trial name
- NCT03237013
- Testing
- Facial Morphing Intervention, Mindfulness Intervention
- Where
- United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- San Diego State University
Advanced Solid Tumors
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors.
- Trial name
- NCT02460224
- Testing
- LAG525, PDR001
- Where
- 24 sites in United States, Australia and 10 more
- Volunteers
- 490 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic, Melanoma
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
The main purpose of this study is to determine how best to combine hypofractionated radiotherapy, MEDI4736, and tremelimumab and to determine how safe and tolerable hypofractionated radiotherapy, MEDI4736, and tremelimumab are…
- Conditions
- Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer
- Trial name
- NCT02639026
- Testing
- Radiotherapy, MEDI4736, Tremelimumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Malignant Solid Neoplasm, Metastatic Melanoma
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors…
- Conditions
- Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04119024
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Anusha Kalbasi
Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC)
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with…
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer
- Trial name
- ARC-12 (NCT04772989)
- Testing
- AB308, Zimberelimab
- Where
- 22 sites in United States, Poland and 1 more
- Volunteers
- 94 people
- Sponsor
- Arcus Biosciences, Inc.
Cutaneous Melanoma
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
This is an international multicenter, open-label, randomized controlled trial (RCT) of single-agent intralesional PV-10 versus systemic chemotherapy or intralesional oncolytic viral therapy to assess treatment of locally advanced…
- Trial name
- NCT02288897
- Testing
- PV-10 (10% rose bengal disodium), Dacarbazine, temozolomide or talimogene laherparepvec
- Where
- 23 sites in United States, France and 3 more
- Volunteers
- 20 people
- Sponsor
- Provectus Biopharmaceuticals, Inc.
Melanoma, Head and Neck Cancer
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Keytruda (pembrolizumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck…
- Conditions
- Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT02475213
- Testing
- Enoblituzumab Schedule 1, Pembrolizumab, Enoblituzumab Schedule 2
- Where
- 20 sites in United States
- Volunteers
- 146 people
- Sponsor
- MacroGenics
Melanoma Stage IV, Melanoma Stage III
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
BERING-MELANOMA - designed as a prospective, longitudinal, non-interventional study - investigates real-world effectiveness, quality of life, safety and tolerability of encorafenib plus binimetinib in unresectable advanced or…
- Trial name
- BERING (NCT04045691)
- Testing
- Encorafenib, Binimetinib
- Where
- 59 sites in Austria, Germany and 1 more
- Volunteers
- 750 people
- Sponsor
- Pierre Fabre Pharma GmbH